VEGFA and wet macular degeneration: Furthermore, in a phase I/II clinical trial of the gene therapy candidate RGX-314, 42 patients with severe wet AMD requiring frequent anti-VEGF injections were stratified into 5 dose groups (ranging from 3 × 109 to 2.5 × 1011 vg/eye).